Comparison · NCT02476409-sae
Tolvaptan vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tolvaptan vs Placebo: serious adverse events. Trial comparisons, record NCT02476409-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02476409-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.316 | 0.154 | 0.54 | wilson | |
| Risk in group 2 | 0.19 | 0.0767 | 0.4 | wilson | |
| Risk difference, group 1 minus group 2 | 0.125 | -0.14 | 0.377 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.66 | 0.55 | 4.99 | log | |
| Odds ratio, group 1 over group 2 | 1.96 | 0.457 | 8.42 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Tolvaptan than on Placebo | 7.98 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tolvaptan | Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily~Tolvaptan: Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure. | 6 | 19 | EG000 |
| Group 2 | Placebo | Augmentation of current dose of loop diuretic~Placebo: Placebo for tolvaptan | 4 | 21 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse event data were collected throughout the 30 day study period
Source ClinicalTrials.gov
Trial
- Title
- Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
- NCT number
- NCT02476409
- Phases
- PHASE4
- Conditions
- Congestive Heart Failure
- Interventions
- tolvaptan, Placebo
- Lead sponsor
- University of North Carolina, Chapel Hill
- Results first posted
- 2022-05-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02476409?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02476409-sae